Business Context and Reporting Period
Company: Humana Inc.
Filing Type: Form 8-K (Current Report)
Reporting Date: May 19, 2026 (Earliest event reported: May 15, 2026)
Event: Entry into Material Definitive Agreements regarding the issuance of Pre-Capitalized Trust Securities (P-Caps) and the establishment of senior note facilities.
Key Financial Metrics and Transaction Details
This filing details a liquidity facility rather than operational financial results. Key transaction metrics include:
- Total Facility Size: $1.5 billion aggregate principal amount ($750 million per Trust).
- 2036 Facility:
- Instrument: 6.062% Senior Notes due 2036.
- Availability Period: 10 years.
- Facility Fee: 1.661% per annum on unexercised portion.
- 2055 Facility:
- Instrument: 6.887% Senior Notes due 2055.
- Availability Period: 30 years.
- Facility Fee: 1.916% per annum on unexercised portion.
- Collateral: Proceeds invested in principal and interest strips of U.S. Treasury securities (Eligible Assets).
Material Changes and Obligations
The filing establishes new off-balance sheet obligations and covenants effective May 15, 2026:
- Automatic Exercise Triggers: Issuance Rights will be exercised automatically upon payment defaults, bankruptcy events, or if Humana's consolidated net worth falls below $4.0 billion.
- Change of Control: Triggers a mandatory repurchase offer for P-Caps at 101% of initial price plus accrued distributions, and Senior Notes at 101% of principal plus accrued interest.
- Redemption Rights: Humana may redeem notes prior to Par Call Dates (Nov 15, 2035 for 2036 Notes; May 15, 2055 for 2055 Notes) at the greater of principal or make-whole price. Post-Par Call Date redemption is at 100% of principal.
- Covenants: Restrictions on creating liens, mergers, consolidations, and asset sales.
Guidance, Outlook, and Risks
Management Commentary: The transaction is designed to provide on-demand capital and liquidity. The filing does not contain forward-looking operational guidance or earnings projections.
Risks and Contingencies:
- Liquidity Risk: Failure to maintain consolidated net worth above $4.0 billion could force immediate debt issuance.
- Cost of Capital: The company incurs facility fees on the unexercised portion of the credit line, representing a cost for maintaining liquidity availability.
- Regulatory Status: P-Caps are sold to qualified institutional buyers and qualified purchasers; they do not carry registration rights.
Investor Verification Checklist
- Verify Humana's current consolidated net worth against the $4.0 billion covenant threshold.
- Review the full text of the Facility Agreements (Exhibits 4.1 and 4.2) for specific default definitions.
- Assess the impact of the facility fees (1.661% and 1.916%) on future interest expense if the lines remain unexercised.
- Confirm the status of the Eligible Assets (U.S. Treasury strips) pledged as collateral.
- Check for any subsequent filings regarding the exercise of Issuance Rights or changes in the company's credit rating.